BNTX BioNTech SE
Price Chart
Executive Summary
BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in first-line NSCLC at ASCO 2026. The data showed high confirmed objective response rates (cORR) of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose, with 100% disease control rate and manageable safety. This supports the ongoing Phase 3 program and positions pumitamig as a potential new standard of care across PD-L1 expression levels.
Actionable Insight
The robust efficacy across PD-L1 subgroups and manageable safety profile de-risk pumitamig's Phase 3 program. Monitor upcoming data from Phase 3 trials (ROSETTA Lung-02, Lung-201, Lung-202) and potential regulatory filings. The partnership with BMS provides strong commercial infrastructure. Near-term catalyst: further Phase 3 readouts in NSCLC and other indications.
Key Facts
- Interim Phase 2 data from ROSETTA Lung-02 trial (NCT06712316) presented at ASCO 2026
- cORR of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower 1400 mg dose
- 100% disease control rate (DCR) across all evaluable patients
- cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%)
- Grade ≥3 treatment-related adverse events in 48.8% of patients; pumitamig-related in 23.3%
- Treatment discontinuation due to AEs in 4 patients (9.3%)
- Phase 3 part of ROSETTA Lung-02 actively enrolling; two additional global Phase 3 trials in NSCLC ongoing
- Seven global Phase 3 trials with registrational potential currently ongoing across multiple indications
Financial Impact
No financial figures provided; clinical data supports potential multi-billion-dollar peak sales opportunity if approved in first-line NSCLC, a large market (~85% of lung cancer cases)
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or show unexpected safety signals
- Competition from existing PD-(L)1 inhibitors and other bispecifics in development
- Regulatory approval not guaranteed; manufacturing and commercial execution risks
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $88.08 awaiting T+5 | awaiting T+5 | — | $85.50 (−2.93%) |
|
Jun 1, 2026
8d ago
|
6-K
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 30, 2026
10d ago
|
Press Release
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $85.50 (−6.76%) |
|
May 22, 2026
18d ago
|
6-K
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.15% | $85.50 (−7.21%) |
|
May 22, 2026
18d ago
|
Press Release
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.14% | $85.50 (−7.21%) |
|
May 15, 2026
25d ago
|
6-K
| $88.85 $92.25 | ▲ +3.83% | ▲ +2.21% | $85.50 (−3.77%) |
|
May 7, 2026
4w ago
|
6-K
| $93.02 $92.23 | ▼ −0.85% | ▼ −2.35% | $85.50 (−8.08%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▲ +1.93% | ▲ +3.91% | $85.50 (+10.47%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▼ −1.93% | ▼ −3.91% | $85.50 (−10.47%) |
|
May 5, 2026
5w ago
|
Press Release
| $95.50 $93.34 | ▼ −2.26% | ▼ −4.25% | $85.50 (−10.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access